TL;DR
This paper presents the first cryo-EM structures of the full-length Follicle Stimulating Hormone Receptor (FSHR) in both inactive and active states, revealing a conserved mechanism of activation across glycoprotein hormone receptors. These structures also shed light on how small molecule agonists activate FSHR, offering a molecular basis for designing more specific drugs for fertility treatments.
What Problem Does This Paper Address?
The Follicle Stimulating Hormone Receptor (FSHR) is crucial for reproduction, and its dysregulation can lead to infertility and ovarian hyperstimulation syndrome. While FSHR is a target for fertility treatments, understanding how it's activated by its natural hormone (FSH) and by small molecule agonists has been challenging due to the lack of full-length receptor structures. Previous studies relied on fragments of the receptor, leading to controversies about its activation mechanism and hindering the development of selective drugs. This paper aims to resolve these ambiguities by providing high-resolution structures of the complete FSHR in its functional states.
Methods
The researchers employed cryo-electron microscopy (cryo-EM) to determine the structures of FSHR. They generated two key structures:
- Active FSHR complex: This involved co-expressing FSHR with a constitutively active mutation (S2731), the Gs protein, and a stabilizing nanobody (Nb35). Human FSH and an allosteric agonist (Cpd-21f) were added to stabilize the complex.
- Inactive FSHR structure: This was obtained by expressing wild-type FSHR in the presence of a small molecule antagonist (compound 24).
After data collection, image processing and map construction were performed using specialized software (MotionCor2, CryoSPARC, RELION, Gctf). Model building and refinement involved using existing crystal structures (FSH-FSHR_ECD, CG-LHCGR-Gs) as templates and iterative adjustments in software like ChimeraX, COOT, and ISOLDE. Functional studies, specifically cAMP response assays, were conducted to assess receptor activation by FSH and various mutants, and to evaluate the potency of allosteric agonists.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Conserved Activation Mechanism: The structures reveal that FSHR activation by FSH shares a conserved "push and pull" mechanism with other glycoprotein hormone receptors (LHCGR and TSHR). This involves an outward rotation of the extracellular domain (ECD) driven by hormone binding.
- Allosteric Agonist Binding: The allosteric agonist Cpd-21f binds to the transmembrane domain (TMD) of FSHR, directly activating it. This binding pocket is similar to those in LHCGR and TSHR, but a unique residue (H615) in FSHR plays a critical role in determining selectivity for allosteric agonists.
- Hinge Region's Role: The extended hinge loop of FSHR is crucial for transmitting the activation signal from the ECD to the TMD, acting as a "pull" mechanism in conjunction with the hormone.
- Molecular Basis for Drug Design: The detailed structures of the active FSHR bound to FSH and Cpd-21f provide a molecular blueprint for designing highly specific small molecule agonists and antagonists for FSHR, which could lead to improved fertility treatments.
- Disease Mutation Insights: The structures also offer a framework for understanding how naturally occurring mutations in FSHR contribute to endocrine diseases.
Key Results
- High-Resolution Structures: The study reports cryo-EM structures of FSH-FSHR-Gs complex at 2.82 Å resolution and inactive FSHR at 6.01 Å resolution.
- FSH-Induced Rotation: FSH binding causes an approximately 48° upward rotation of the FSHR ECD, a movement conserved across related receptors.
- Allosteric Agonist Selectivity: The residue H615 in FSHR is identified as a key determinant for allosteric agonist selectivity, with mutations at this site significantly altering the receptor's response to different ligands.
- Functional Validation: cAMP assays confirmed the activation potency of FSH and Cpd-21f, and demonstrated the impact of various mutations on receptor activity and ligand selectivity.
Limitations and Future Work
- Inactive Structure Resolution: The inactive FSHR structure was obtained at a lower resolution (6.01 Å), limiting detailed atomic modeling.
- In Vitro vs. In Vivo: The studies were conducted using purified proteins and cell-based assays, and future work could explore these mechanisms in more complex in vivo models.
- Drug Development: While the structures provide a basis for drug design, further research is needed to develop clinically viable FSHR-targeted drugs with improved specificity and efficacy. The authors suggest that understanding the selectivity determinants, like H615, is crucial for this endeavor.
- Broader Receptor Family: The findings on FSHR activation are proposed to be universally applicable to the glycoprotein hormone receptor family, warranting further investigation into LHCGR and TSHR in similar detail.
Summary updated